- Home
- CRVS vs PLBC Comparison
CRVS vs PLBC Comparison
Compare CRVS & PLBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- PLBC
- Stock Information
- Founded
- CRVS 2014
- PLBC 1980
- Country
- CRVS United States
- PLBC United States
- Employees
- CRVS N/A
- PLBC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- PLBC Finance Companies
- Sector
- CRVS Health Care
- PLBC Finance
- Exchange
- CRVS Nasdaq
- PLBC Nasdaq
- Market Cap
- CRVS 206.5M
- PLBC 236.7M
- IPO Year
- CRVS 2016
- PLBC 2005
- Fundamental
- Price
- CRVS $3.63
- PLBC $41.56
- Analyst Decision
- CRVS Strong Buy
- PLBC Buy
- Analyst Count
- CRVS 3
- PLBC 3
- Target Price
- CRVS $15.67
- PLBC $57.67
- AVG Volume (30 Days)
- CRVS 906.6K
- PLBC 13.3K
- Earning Date
- CRVS 05-05-2025
- PLBC 04-16-2025
- Dividend Yield
- CRVS N/A
- PLBC 2.89%
- EPS Growth
- CRVS N/A
- PLBC 3.33
- EPS
- CRVS N/A
- PLBC 4.95
- Revenue
- CRVS N/A
- PLBC $84,001,000.00
- Revenue This Year
- CRVS N/A
- PLBC $19.95
- Revenue Next Year
- CRVS N/A
- PLBC $22.19
- P/E Ratio
- CRVS N/A
- PLBC $8.40
- Revenue Growth
- CRVS N/A
- PLBC 9.14
- 52 Week Low
- CRVS $1.43
- PLBC $32.50
- 52 Week High
- CRVS $10.00
- PLBC $51.33
- Technical
- Relative Strength Index (RSI)
- CRVS 55.04
- PLBC 53.61
- Support Level
- CRVS $3.15
- PLBC $39.81
- Resistance Level
- CRVS $3.78
- PLBC $43.02
- Average True Range (ATR)
- CRVS 0.25
- PLBC 1.91
- MACD
- CRVS 0.12
- PLBC 0.22
- Stochastic Oscillator
- CRVS 87.90
- PLBC 63.43
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.